You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Benzimidazole

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Benzimidazole?

Benzimidazole is an investigational drug.

There have been 13 clinical trials for Benzimidazole. The most recent clinical trial was a Phase 1 trial, which was initiated on November 11th 2019.

The most common disease conditions in clinical trials are Helminthiasis, Neoplasms, Plasma Cell, and Anemia, Hemolytic. The leading clinical trial sponsors are Sidney Kimmel Comprehensive Cancer Center, University Ghent, and University of Washington.

There are two US patents protecting this investigational drug and forty international patents.

Recent Clinical Trials for Benzimidazole
Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in GabonCentre de Recherche Médicale de LambarénéPhase 4
Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric PatientsAlejandro KrolewieckiPhase 2
Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic ResistanceSwiss Tropical & Public Health InstituteN/A

See all Benzimidazole clinical trials

Clinical Trial Summary for Benzimidazole

Top disease conditions for Benzimidazole
Top clinical trial sponsors for Benzimidazole

See all Benzimidazole clinical trials

US Patents for Benzimidazole

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Benzimidazole   Start Trial Compositions and methods of rinsable primers used to aid in the removal of temporary functional coatings   Start Trial
Benzimidazole   Start Trial Materials for organic light emitting diode UNIVERSAL DISPLAY CORPORATION (Ewing, NJ)   Start Trial
Benzimidazole   Start Trial Fused pyrimidines as inhibitors of P97 complex Cleave Biosciences, Inc. (Burlingame, CA)   Start Trial
Benzimidazole   Start Trial Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes APOGLYX AB (Lund, SE)   Start Trial
Benzimidazole   Start Trial Aromatic amine derivative, and organic electroluminescent element using same IDEMITSU KOSAN CO., LTD. (Chiyoda-ku, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Benzimidazole

Drugname Country Document Number Estimated Expiration Related US Patent
Benzimidazole Taiwan 201425503 2032-10-12   Start Trial
Benzimidazole World Intellectual Property Organization (WIPO) 2014059094 2032-10-12   Start Trial
Benzimidazole China 101657518 2027-03-08   Start Trial
Benzimidazole China 102911213 2027-03-08   Start Trial
Benzimidazole China 103087109 2027-03-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.